Minimal Residual Disease in Breast Cancer: an Overview of Circulating and Disseminated Tumour Cells

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2016 May 19

PMID 27189371

Citations 22

Authors

A Tachtsidis

L M McInnes

N Jacobsen

E W Thompson

C M Saunders

Affiliations

Soon will be listed here.

Abstract

Within the field of cancer research, focus on the study of minimal residual disease (MRD) in the context of carcinoma has grown exponentially over the past several years. MRD encompasses circulating tumour cells (CTCs)-cancer cells on the move via the circulatory or lymphatic system, disseminated tumour cells (DTCs)-cancer cells which have escaped into a distant site (most studies have focused on bone marrow), and resistant cancer cells surviving therapy-be they local or distant, all of which may ultimately give rise to local relapse or overt metastasis. Initial studies simply recorded the presence and number of CTCs and DTCs; however recent advances are allowing assessment of the relationship between their persistence, patient prognosis and the biological properties of MRD, leading to a better understanding of the metastatic process. Technological developments for the isolation and analysis of circulating and disseminated tumour cells continue to emerge, creating new opportunities to monitor disease progression and perhaps alter disease outcome. This review outlines our knowledge to date on both measurement and categorisation of MRD in the form of CTCs and DTCs with respect to how this relates to cancer outcomes, and the hurdles and future of research into both CTCs and DTCs.

Citing Articles

Cellular residual disease (CRD) in early breast cancer -Expanding the concept of minimal residual disease monitoring?.

Serafini M, Molteni E, Nicolo E, Gerratana L, Reduzzi C, Cristofanilli M J Liq Biopsy. 2025; 3:100132.

PMID: 40026561 PMC: 11863885. DOI: 10.1016/j.jlb.2023.100132.

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I Nat Commun. 2024; 15(1):2691.

PMID: 38538574 PMC: 10973408. DOI: 10.1038/s41467-024-46961-x.

Inhaled anesthesia associated with reduced mortality in patients with stage III breast cancer: A population-based study.

Kuo E, Kuo C, Lin C PLoS One. 2024; 19(3):e0289519.

PMID: 38427628 PMC: 10906904. DOI: 10.1371/journal.pone.0289519.

Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation?.

Witz A, Dardare J, Betz M, Gilson P, Merlin J, Harle A Clin Exp Med. 2024; 24(1):2.

PMID: 38231464 PMC: 10794481. DOI: 10.1007/s10238-023-01278-9.

Cellular Dormancy in Cancer: Mechanisms and Potential Targeting Strategies.

Min H, Lee H Cancer Res Treat. 2023; 55(3):720-736.

PMID: 36960624 PMC: 10372609. DOI: 10.4143/crt.2023.468.

References

Pantel K, Alix-Panabieres C . Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010; 16(9):398-406. DOI: 10.1016/j.molmed.2010.07.001. View

Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R . Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012; 72(6):1384-94. PMC: 8543151. DOI: 10.1158/0008-5472.CAN-11-2905. View

Gupta P, Chaffer C, Weinberg R . Cancer stem cells: mirage or reality?. Nat Med. 2009; 15(9):1010-2. DOI: 10.1038/nm0909-1010. View

Borst P . Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?. Open Biol. 2012; 2(5):120066. PMC: 3376736. DOI: 10.1098/rsob.120066. View

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N . Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011; 9:131. PMC: 3214885. DOI: 10.1186/1477-7819-9-131. View

Makki J . Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol. 2016; 8:23-31. PMC: 4689326. DOI: 10.4137/CPath.S31563. View

Mundy G . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2(8):584-93. DOI: 10.1038/nrc867. View

Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C . HER2-positive circulating tumor cells in breast cancer. PLoS One. 2011; 6(1):e15624. PMC: 3018524. DOI: 10.1371/journal.pone.0015624. View

10.

Liedtke C, Broglio K, Moulder S, Hsu L, Kau S, Symmans W . Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009; 20(12):1953-8. PMC: 2791352. DOI: 10.1093/annonc/mdp263. View

11.

Kerr C, Hussain A . Regulators of prostate cancer stem cells. Curr Opin Oncol. 2014; 26(3):328-33. DOI: 10.1097/CCO.0000000000000080. View

12.

Thompson E, Haviv I . The social aspects of EMT-MET plasticity. Nat Med. 2011; 17(9):1048-9. DOI: 10.1038/nm.2437. View

13.

Kallergi G, Papadaki M, Politaki E, Mavroudis D, Georgoulias V, Agelaki S . Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011; 13(3):R59. PMC: 3218948. DOI: 10.1186/bcr2896. View

14.

Cawthorn T, Amir E, Broom R, Freedman O, Gianfelice D, Barth D . Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis. 2009; 26(8):935-43. DOI: 10.1007/s10585-009-9284-5. View

15.

Wasserman L, Dreilinger A, Easter D, Wallace A . A seminested RT-PCR assay for HER2/neu: initial validation of a new method for the detection of disseminated breast cancer cells. Mol Diagn. 1999; 4(1):21-8. DOI: 10.1016/s1084-8592(99)80046-0. View

16.

Zhang Y, Ma Q, Liu T, Ke S, Jiang K, Wen Y . Tumor self-seeding by circulating tumor cells in nude mouse models of human osteosarcoma and a preliminary study of its mechanisms. J Cancer Res Clin Oncol. 2013; 140(2):329-40. DOI: 10.1007/s00432-013-1561-7. View

17.

Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E . Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer. 2010; 129(2):417-23. DOI: 10.1002/ijc.25690. View

18.

Abraham B, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H . Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005; 11(3):1154-9. View

19.

Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M . VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell. 2011; 20(6):701-14. PMC: 3241854. DOI: 10.1016/j.ccr.2011.11.002. View

20.

Wulfing P, Borchard J, Buerger H, Heidl S, Zanker K, Kiesel L . HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006; 12(6):1715-20. DOI: 10.1158/1078-0432.CCR-05-2087. View